Biopharma · FDA Approvals · Stock
Agios Pharmaceuticals Inc is a biopharmaceutical company focused on the field of cellular metabolism to create differentiated medicines for rare diseases, with a focus on classical hematology. The company's primary focus is to develop potentially transformative small-molecule medicines. Its product candidate, Pyrukynd …
Assets on file: mitapivat
Dated catalysts for AGIO, including recently decided ones.
Agios mitapivat sNDA PDUFA for sickle cell disease extended to Feb 1, 2027
Rescheduled — was Nov 1, 2026
Every first-hand event for AGIO, newest first.
mitapivat · NCT05935202 registry update
status: NOT_YET_RECRUITING → ACTIVE_NOT_RECRUITING; primary_completion: 2025-07-15 → 2028-09-30; completion: 2026-12-15 → 2029-03-30
Agios mitapivat sNDA PDUFA for sickle cell disease extended to Feb 1, 2027
FDA extended the PDUFA goal date for the mitapivat sNDA in sickle cell disease by three months to February 1, 2027 after classifying Agios' response to a REMS-related information request as a major amendment. The company remains launch-ready and is continuing labeling discussions with the FDA.
mitapivat · NCT07656415 registry update
countries: {'total_sites': 3, 'us_sites': 3} → {'total_sites': 5, 'us_sites': 5}
mitapivat · NCT07055243 registry update
status: RECRUITING → ACTIVE_NOT_RECRUITING; primary_completion: 2026-06-30 → 2029-10; completion: 2027-06-30 → 2029-10
mitapivat · NCT07517133 registry update
countries: {'total_sites': 4, 'us_sites': 4} → {'total_sites': 5, 'us_sites': 5}
Agios: FDA sets Nov 1, 2026 PDUFA for mitapivat sNDA in sickle cell disease
FDA granted Priority Review and set a PDUFA goal date of November 1, 2026 for the mitapivat sNDA in sickle cell disease. The application was submitted under the accelerated approval pathway and will require a confirmatory Phase 3 trial (REIGNITE) to verify clinical benefit. This establishes a near-term regulatory decision point for a potential new indication.
Agios presents RISE UP Phase 3 mitapivat data at EHA 2026 plenary
Agios presented detailed 52-week RISE UP Phase 3 results at the EHA 2026 plenary session, showing statistically significant hemoglobin response (40.6% vs 2.9%) and clinically meaningful transfusion burden reduction (41.1% fewer patients transfused). Post-hoc analyses demonstrated that hemoglobin responders experienced meaningful reductions in sickle cell pain crises, hospitalizations, and fatigue, reinforcing mitapivat's anti-hemolytic profile ahead of its sNDA submission for accelerated approval.
Agios submits sNDA for mitapivat accelerated approval in sickle cell disease
Agios has submitted an sNDA to FDA for accelerated approval of mitapivat in sickle cell disease. The submission follows FDA agreement on a required confirmatory trial designed to show transfusion-burden reduction. FDA filing acceptance and review timeline are expected in Q3 2026 after the 60-day filing review period.
Agios plans mitapivat sNDA submission for sickle cell disease in Q2 2026
Agios confirmed it will submit an sNDA for mitapivat in sickle cell disease under the FDA accelerated approval pathway in the second quarter of 2026 after completing its pre-sNDA meeting with the FDA. The filing follows the company’s earlier thalassemia approvals and is positioned as the next regulatory step for the asset.
Agios: FDA approves AQVESME (mitapivat) for thalassemia anemia
FDA approved AQVESME (mitapivat) in December 2025 as the only medicine for anemia in adults with alpha- or beta-thalassemia regardless of transfusion burden. The product is now available in the U.S. following REMS implementation in late January 2026. This converts the regulatory path from pending to approved and launches commercial availability.
Agios: pre-sNDA FDA meeting for mitapivat in sickle cell disease set for Q1 2026
The press release states that Agios will hold a pre-sNDA meeting with the FDA in Q1 2026 for mitapivat in sickle cell disease, after which the company plans to submit a U.S. marketing application. This sets the next regulatory milestone for the sickle cell indication following the November 2025 topline readout.
Agios: FDA extends PYRUKYND thalassemia sNDA PDUFA to Dec 7, 2025
FDA extended the PDUFA goal date for the PYRUKYND sNDA in thalassemia by three months to December 7, 2025 after requesting a REMS for potential hepatocellular injury risk. The extension was not due to new efficacy or safety data; the application remains under active FDA review with U.S. launch preparations ongoing.
Companies in the same sector closest to AGIO in market value.